PURPOSE: To report on the clinical use of subconjunctival bevacizumab in patients with corneal neovascularization. METHODS: The charts of 10 consecutive patients with corneal neovascularization who received subconjunctival injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Digital photographs of the cornea were graded by 2 masked observers for density, extent, and centricity of corneal vascularization. Image analysis was used to determine the area of cornea covered by neovascularization as a percentage of the total corneal area. RESULTS: No significant ocular or systemic adverse events were observed during 3.5 ± 1.1 months of follow-up. Seven patients showed partial regression of vessels. The extent decreased from 6.0 ± 1.2 (SD) clock hours before the injection to 4.6 ± 1.0 clock hours after bevacizumab injection (P = 0.008). Density decreased from 2.7 ± 0.2 to 1.9 ± 0.3, respectively. (P = 0.007). No change was noticed in the centricity of corneal vessels. Corneal neovascularization covered, on average, 14.8% ± 2.5% (SD) of the corneal surface before the injections, compared with 10.5% ± 2.8% (P = 0.36, t test) after bevacizumab injection. Therefore, bevacizumab decreased corneal neovascularization by 29%. CONCLUSIONS: Short-term results suggest that subconjunctival bevacizumab is well tolerated and associated with a partial regression of corneal neovascularization.
- Corneal neovascularization